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Abstract 
 
The syntheses of tetra-tetrazole macrocycles containing at least one 2,6-bis(tetrazole)pyridine 
unit, linked by a variety of n-alkyl (n = 3, 5, 7 or 9 carbon atoms) chain lengths, are described. 
There has been no previous incorporation of the pyridine moiety into a tetra-tetrazolophane 
macrocycle. The crystal structure of one such tetra-tetrazole macrocycle has also been 
structurally characterised and revealed a bowl-shaped conformation. 
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Introduction 
 
There are many articles and reviews on tetrazoles in the literature, including their use as 
carboxylic acid bioisosteres in drug discovery and as functional ligands in coordination 
chemistry.
1-5
 The development of “click” chemistry methodology, as described by Sharpless and 
co-workers,
6,7
 has resulted in a recent increase in tetrazole structures, which suggests that 
molecular recognition studies of tetrazoles will become increasingly important.
8-15
 We are 
interested in tetrazoles as precursors for the formation of new functionalised polytetrazole 
macrocycles, which could find application, for example, as sensors or in molecular recognition. 
We have previously reported the synthesis and structural characterisation of tetra-tetrazole 
macrocycles from 1,2-, 1,3- and 1,4-dicyanobenzene derivatives as well as the first example of a 
host-guest interaction between a tetra-tetrazole macrocycle and a solvent molecule.
16-18
 Previous 
work in our group has shown that the use of odd-numbered carbon chains gave higher yields than 
when even-numbered chains were used.
18
 This paper focuses on the synthesis and 
characterisation of bis-tetrazoles from 2,6-pyridinedicarbonitrile (1), their n-alkyl halide 
derivatives (where n = 3, 5, 7 or 9), and their resulting tetra-tetrazole macrocycles (see Scheme 
1). To our knowledge, there has been no previous incorporation of the pyridine moiety into a 
tetra-tetrazolophane macrocycle. The X-ray crystal structure of one such macrocyclic derivative 
(7c), which is obtained from the reaction of 3c with 1,3-bis(tetrazol-5-yl)benzene (6), is also 
described. 
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Scheme 1. Reagents and conditions: (i) NaN3, NH4Cl, LiCl, DMF, 110 
o
C, 10 h; (ii) 1,n-
dibromoalkane (n = 3, 5, 7, 9), Et3N, MeOH, ∆, 24 h; (iii) 2, K2CO3, DMF, 75 
o
C, 24 h; iv) 6, 
K2CO3, DMF, 75 
o
C, 24 h. 
 
Results and Discussion 
 
Syntheses and characterisation of bis-tetrazoles 
 
The reaction of 2,6-pyridinedicarbonitrile (1) with sodium azide was carried out, following a 
similar procedure to that we have previously described,
19
 to give 2,6-di(2H-tetrazol-5-yl)pyridine 
(2) in good yield. The IR spectrum of 2 showed the indicative loss of the nitrile and azide bands 
at ca. 2200 and ca. 2060 cm
-1
, respectively. The 
1
H NMR spectrum of 2 showed a multiplet at 
8.32 ppm due to the pyridyl ring proton signals, and a broad singlet at 3.56 ppm due to the NH 
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proton. The 
13
C NMR spectrum confirmed the formation of the tetrazole system with the signal at 
158.5 ppm, indicative of the tetrazole moiety.
16-19
  
 
The alkylation of 2 was carried out using the appropriate α,ω-dibromoalkane in the presence of 
triethylamine as base in methanol for three hours at reflux temperature. In each case, after cooling 
and reaction work-up, only two products were obtained, which were purified by column 
chromatography on silica gel. These products were the N2,N1' (major) (3a-d) and N2,N2' (minor) 
(4a-d) di-alkylated systems. The melting points of the symmetric and asymmetric products 
differed. It was observed that the symmetric analogues N2,N2' had slightly higher melting point 
values, which may have been due to the symmetric system experiencing greater intermolecular 
bonding. 
 
The range of asymmetric product yields (3a-d) varied from 17%-37% (see experimental) and 
were considerably higher than the symmetric products (4a-d). It was observed that as the chain 
length increased the yield also increased. This may be due to the possibility of the species 
containing shorter chains forming polymeric adducts. The IR spectra of 3a-d showed the 
characteristic bands of the tetrazole at 1668, 1523 and 1254 cm
-1
 and the >C=N- band of the 
pyridine at 1458 cm
-1
 respectively. The 
1
H NMR spectra of 3a-d clearly showed the asymmetry 
that is present in the products. The aromatic protons that are ortho to the tetrazole rings are both 
split into two separate doublets at 8.50 ppm, beside the N1 tetrazole ring, and at 8.38 ppm for the 
N2 tetrazole ring of 3a. The pseudo-triplet signal for the remaining proton on the pyridine ring at 
8.12 ppm is not affected by asymmetry, probably due to its distance from the point of asymmetry. 
The methylene groups directly attached to the tetrazole ring appear as two separate triplets in the 
1
H NMR spectra of 3a-d with the N1-CH2 triplet being observed at 5.25 ppm and the N2-CH2 
signal being observed at 4.96 ppm in 3a. The signal associated with the CH2Br appeared at ~3.4 
ppm as a multiplet in all compounds in the series apart from compound 3a, where two triplets at 
3.62 ppm and 3.51 ppm (N1 and N2) were observed. This was probably due to the short distance 
from the N1 and N2 alkylated tetrazoles to the CH2Br. As a comparison, in the 
1
H NMR spectra 
of the 1,3-bis[(bromoalkylyl)tetrazol-5-yl]benzene (2-N, 2-N’),18 the N2-CH2 signals appear at 
~4.70 ppm while those for the CH2Br appear at ~3.40 ppm. All other methylene signals can be 
observed as multiplets between 2.1-1.3 ppm. The 
13
C NMR spectra of 3a-d also showed the 
asymmetric nature of the product with two tetrazole peaks at ~164 ppm for the N2 substituted 
tetrazole and ~151 ppm for the N1 substituted tetrazole.  
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The 
1
H NMR spectra for the symmetric bis-tetrazoles 4a-d are much simpler that those observed 
for the asymmetric bis-tetrazoles 3a-d, just discussed. The aromatic protons, ortho to the tetrazole 
rings, appear as as a single doublet at ~8.36 ppm while the remaining proton on the pyridine ring 
appears as a triplet at ~8.38 ppm. Furthermore, the methylene groups directly attached to the 
tetrazole ring now appear as a single triplet in the 
1
H NMR spectra of 4a-d at 4.95 ppm for 4a 
and at ~4.75 ppm for 4b-d. The 
13
C NMR spectra confirmed the symmetric nature of the 
compounds with a signal at 164.4 ppm, due to the tetrazoles being substituted in the N2 position. 
The IR spectra of 4a-d were very similar to those of the asymmetric derivatives. Apart from the 
NMR spectra, the other major difference between the asymmetric and symmetric derivatives was 
in the yield of material recovered. The yield of the symmetric products 4a-d was surprisingly 
low, falling in the range of 2-5 %. One possible reason for these low yields in the symmetric 
cases may be the presence of a pyridinium salt, formed during the acidification work-up of the 
bis-tetrazole derivative 2. Due to the difference in pKa between pyridine (ca. pKa 5.2) and 
tetrazole (ca. pKa 4.5), it is believed that the pyridine nitrogen will be protonated. However, this 
does not explain the difference in yield between the asymmetric and symmetric derivatives, as 
this pyridinium salt would also have been present in the reaction. 
 
X-Ray crystal structure of 3b 
 
Crystals of compound 3b, suitable for an X-ray diffraction study, were obtained as colourless 
plates by the diffusion method of chloroform in methanol. The diffraction data were of poor 
quality but the significant features of the structure are clear. The structure confirmed the presence 
of the pendant bromoalkyl groups substituted in the N2,N1' positions, see Figure 1. 
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Figure 1. Molecular structure of 3b with displacement ellipsoids at the 50% probability level for 
non-H atoms. 
 
One of the tetrazole rings and the pyridine ring are almost co-planar, with the other tetrazole ring 
being distinctly tilted relative to the other two rings. Both bromohexyl arms lie on the same face 
of the pyridine ring. A - interaction between neighbouring molecules is observed and shown 
in Figure 2. 
 
 
 
Figure 2. Observed - interaction of 3b. 
 
Synthesis of pyridyl-tetra-tetrazole macrocycles 
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Since the yields of the asymmetric alkylated bis-tetrazoles (3a-d) were substantially better than 
those of the symmetric derivatives, it was decided to attempt the synthesis of an asymmetric 
pyridine tetra-tetrazole macrocycle. When an asymmetric alkylated product (3a-d) was reacted 
with 2,6-bis-(2H-tetrazol-5-yl)-pyridine (2) using previously reported conditions,
18
 a number of 
products were observed by TLC analysis. However, these products could not be separated by 
conventional chromatography methods. This may have been due to the likelihood of pyridine 
macrocycles (N2,N1',N2'',N1''') and (N2,N1',N1'',N2''') having similar Rf values. The 
1
H NMR 
spectra of the single spot by TLC for each of the tetra-tetrazole macrocycles (5a-d) were very 
complicated but clearly showed signals for two macrocycles (N2,N1',N2'',N1''') and 
(N2,N1',N1'',N2'''). 
 
We have previously reported the synthesis and structural characterisation of tetra-tetrazole 
macrocycles from 1,2-, 1,3- and 1,4-dicyanobenzene derivatives, using alkyl linkers.
16,18
 The 
cyclisation reaction, in all cases, formed predominantly the symmetric product, where the alkyl 
chains are joined to the tetrazole moieties at the N2 position, with very little asymmetry being 
observed. It was therefore postulated that if the asymmetric alkylated products (3a-d) were 
clipped with 1,3-bis(tetrazol-5-yl)benzene (6) that one major product would be obtained, which 
was the alkylation of the 2N,2N' positions of 1,3-bis(tetrazol-5-yl)benzene (see Experimental 
section). The major products in all of these reactions were the (N2,N2',N2'',N1''') macrocycles 
(7a-d), with high yields of ~40% in all cases, except in the case of 7d which is probably due to 
the difficulty in forming the large ring system. The HRMS results obtained for the four products 
(7a-d) confirmed the formation of the macrocycles. 
 
The IR spectra of 7a-d were very similar to those of the alkylated precursors (3a-d) with 
characteristic shifts for pyridine, tetrazole and phenyl ring systems being observed (see 
Experimental). In the 
1
H NMR spectra of all the cyclisation products, the signal for the CH2Br at 
~3.4 ppm had disappeared, and the accompanying loss of the CH2Br signal in the 
13
C NMR 
spectra confirmed that cyclisation had occurred. The 
1
H NMR spectra of 7a-d have a complex 
aromatic region. The signals in the 
1
H NMR spectrum of 7a at 8.41(s), 8.17(d) and 7.60(t) ppm 
are due to the protons of the phenyl ring while those at 8.31(d), 8.04(d) and 7.91(t) ppm are due 
to the protons on the pyridine ring. The aromatic regions in the 
1
H NMR spectra of 7b-d are 
similar. The asymmetric nature of the macrocycle is observed by the appearance of two sets of 
doublets for the pyridine protons ortho to the different tetrazole rings. This asymmetry also 
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manifests itself in the signals of the methylene groups attached to the tetrazole rings. A triplet is 
observed at 5.30 ppm for the methylene protons attached to the tetrazole ring at N1. A multiplet 
for the methylene protons attached to the symmetric 1,3-bis(tetrazol-5-yl)benzene is observed at 
5.03 ppm. Another multiplet is observed at 4.74 ppm for the methylene group bonded to the 
second tetrazole attached to the pyridine group. These two multiplets at 5.03 and 4.74 ppm are 
not observed as the alkyl chain increases, presumably because the environment in which the 
methylene groups attached to the N2-tetrazole becomes similar. In compounds 7b-d, a single 
multiplet is observed at ca. 4.70 ppm, which accounts for the 6 protons associated with the N2-
CH2 substituted tetrazoles. The remaining alkyl protons appear at 1.67 ppm. With increased alkyl 
chain length further multiplets can be observed at ca. 2.10 ppm. 
 
The 
13
C NMR spectra of 7a-d confirmed the macrocyclic structure with three signals observed at 
164.6, 164.2 and 163.9 ppm, respectively, for the N2-substituted tetrazoles. A single signal was 
observed at 151.5 ppm for the N1-substituted tetrazole, confirming the substitution pattern of the 
macrocycles. Furthermore, four peaks are observed for the methylene carbons adjacent to the 
tetrazole nitrogens at 51.3, 50.4 and 49.4 ppm for the N2 substituted tetrazoles and 46.1 ppm for 
the N1 substituted tetrazole.  
 
X-Ray Crystal Structure of 7c 
 
Crystals of 7c were obtained from chloroform solution, and the crystal structure confirms the 
expected tetra-tetrazole macrocyclic structure, with three of the tetrazole rings substituted at the 
N2 position and one tetrazole ring substituted at the N1 position, as suggested by 
13
C NMR 
spectroscopy (Figure 3). The structure also shows that N8 of one tetrazole ring and N9 of the 
pyridine ring are potentially available for use as metal ion chelators. 
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Figure 3. Molecular structure of 7c with displacement ellipsoids at the 50% probability level for 
non-H atoms. 
 
Bond lengths and angles are similar to other tetrazole macrocyclic compounds we have 
previously reported.
16,18
 One striking difference between 7c and a macrocycle which contains two 
phenyl rings, such as 8,
16
 is the overall geometry of both macrocycles, which is bowl-shaped in 
the case of 7c (Figure 4) but is more step-like in 8 (Figure 5). This geometry change is likely to 
be a packing effect due to the different alkyl chain lengths. Furthermore, there is now only one 
 interaction present between the ring containing N10-N13 and its symmetry equivalent (under 
symmetry operation 1-x, 1-y, z), with a centroid-centroid distance of 3.478 Å, which results in the 
packing arrangement shown in Figure 7. This type of arrangement is different to that observed in 
8 where adjacent macrocycles are arranged so that one benzene-tetrazole unit lies over the cavity 
of the adjacent macrocycle (Figure 5), forming a local stacking arrangement.   
 
Figure 4. Side view of 7c. 
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Figure 5. Molecular structure of 8 showing displacement ellipsoids at the 50% probability level 
for non-H atoms (left), and a stacking interaction between adjacent macrocycles in 8 (right).
16
 
 
 
Figure 6. Unit cell of 7c viewed down the a axis, showing the packing arrangement of the 
macrocycle. 
 
Conclusions 
 
In this paper, we have reported the syntheses and characterisation of bromo-alkyl derivatives of 
2,6-bis(tetrazole)pyridine, where the alkyl chain contains either 3, 5, 7 or 9 carbons atoms. 
Interestingly, the predominant compound formed in these reactions is the asymmetric 1-N,2-N’-
bistetrazole isomer, whereas the same reactions carried out with 1,3-bis(tetrazole)benzene have 
previously yielded symmetric 2-N,2-N’-bistetrazole derivatives. Four new tetra-tetrazole 
macrocycles, containing one pyridine ring, were synthesised and the X-ray crystal structure of 
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one such macrocycle (7c) showed a bowl-shaped conformation. Complexation studies of these 
new tetra-tetrazole macrocycles with various metal ions are currently being undertaken. 
 
Experimental 
 
All reagents and solvents were commercially obtained and used without further purification. The 
petroleum ether used for chromatography was 40:60 reagent grade. 
1
H and 
13
C NMR (δ ppm; J 
Hz) spectra were recorded on a JEOL JNM-LA300 FT-NMR spectrometer using saturated CDCl3 
solutions with Me4Si reference, unless indicated otherwise. Infrared spectra (cm
-1
) were recorded 
as KBr discs or liquid films between KBr plates using a Nicolet Impact 410 FT-IR 
spectrophotometer. Melting point analysis was carried out using either a Stewart Scientific SMP1 
or a Mettler FP62 melting point apparatus and are uncorrected. Microanalysis was carried out at 
the Microanalytical Laboratory of University College, Dublin. Mass spectrometry was carried out 
at the Centre for Synthesis and Chemical Biology (CSCB), University College, Dublin using 
Quattro micro
TM
 LC-MS/MS and LCT mass spectrometers. Standard Schlenk techniques were 
used throughout. The synthesis of compounds 6
19
 has been described previously. 
 
CAUTION: Owing to their potentially explosive nature, all preparations of and subsequent 
reactions with azides and tetrazoles were conducted under an inert atmosphere behind a rigid 
safety screen. 
 
Synthesis of 2,6-di(2H-tetrazol-5-yl)pyridine (2) 
 
A suspension of 2,6-pyridinedicarbonitrile (2.57 g, 20 mmol), sodium azide (2.86 g, 43 mmol), 
ammonium chloride (2.35 g, 43 mmol) and lithium chloride (0.6 g, 14 mmol) in anhydrous 
dimethylformamide (60 mL) was stirred for 10 hours at 110 
o
C. After this time, the solution was 
cooled and the insoluble salts were removed by filtration. The solvent was then evaporated under 
reduced pressure and the residue was dissolved in deionised water (200 mL) and acidified with 
concentrated HCl (3 mL), to initiate precipitation. The product was filtered, washed with water (3 
x 40 mL) and dried to give 2,6-di(2H-tetrazol-5-yl)pyridine (2) as a white crystalline powder. 
Purification by recrystallisation from methanol to give white needles of 2 (3.08 g, 14.3 mmol, 72 
%); mp > 300 °C; IR (KBr cm
-1
) 3415 (N-H), 2851, 1654, 1596, 1458, 1278; 
1
H NMR (300 
MHz, (CD3)2SO): δH 8.49 (1H, t, J = 7.8 Hz, ArH), 8.23 (2H, d, J = 7.6 Hz, ArH), 3.56 (2H, s 
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(br), NH); 
13
C NMR (75.4 MHz, (CD3)2SO): δC 158.5, 145.5, 142.9, 119.3, 125.4. Anal. Calcd 
for C7H5N9: C, 39.07; H, 2.34; N, 58.59%. Found C, 38.98; H, 2.36; N, 58.45%. 
 
General Syntheses of alkylated bis-tetrazoles (3 & 4) 
 
Compound 2 (1.51 g, 7.0 mmol) was dissolved in methanol (60 ml) and to the stirred solution 
was added triethylamine (4.23 ml, 42 mmol). The resulting solution was stirred at reflux 
temperature for 30 minutes, then to the hot solution was added the corresponding dibromoalkane 
(21.0 mmol). The reaction mixture was then stirred at reflux for a further 24 hours. On cooling, 
the solid was removed by filtration and the solvent was removed from the filtrate under vacuum. 
The resulting products were purified by column chromatography on silica gel (initially @ a ratio 
of petroleum ether:ethyl acetate 70:30, followed by the ratio 60:40). 
 
2-[2-(3-Bromopropyl)-2H-tetrazol-5-yl]-6-[1-(3-bromopropyl)-1H-tetrazol-5-yl]pyridine (3a) 
 
White solid (0.55 g, 1.2 mmol, 17.2 %); mp 88-90 °C; Rf = 0.32 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2968, 1668 (>C=N-), 1523 (-N=N-), 1458 (C=N, pyridine), 1434, 1254; 
1
H NMR (300 MHz, CDCl3): δH 2.67 (4H, m, CH2), 3.51 (2H, t, J = 6.1 Hz, CH2Br (N2)), 3.62 
(2H, t, J = 6.6 Hz, CH2Br (N1)), 4.96 (2H, t, J = 6.6 Hz, CH2N2), 5.25 (2H, t, J = 6.7 Hz, 
CH2N1), 8.12 (1H, t, J = 7.8 Hz, pyH), 8.38 (1H, d, J = 7.8 Hz, pyH), 8.50 (1H, d, J = 7.8 Hz, 
pyH); 
13
C NMR (75.4 MHz, CDCl3): δC 28.7, 29.3, 31.9, 32.9, 48.9, 51.6, 124.0, 125.3, 138.5, 
145.0, 146.7, 151.4, 164.1. Anal. Calcd for C13H15N9Br2: C, 34.16; H, 3.31; N, 27.58%. Found: 
C, 34.48; H, 3.44; N, 27.21%. 
 
2,6-Bis[2-(3-bromopropyl)-2H-tetrazol-5-yl]-pyridine (4a) 
 
White solid (0.10 g, 0.22 mmol, 3.1 %); mp 94-96 °C; Rf = 0.21 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2922, 2855, 1648 (>C=N-), 1587 (-N=N-), 1459 (C=N, pyridine), 1436, 
1263; 
1
H NMR (300 MHz, CDCl3): δH 2.68 (4H, q, J = 6.1 Hz, CH2), 3.48 (4H, t, J = 6.8 Hz, 
CH2Br), 4.95 (4H, t, J = 6.8 Hz, CH2N), 8.02 (1H, t, J = 7.8 Hz, pyH), 8.37 (2H, d, J = 7.8 Hz, 
pyH); 
13
C NMR (75.4 MHz, CDCl3): δC 29.7, 31.8, 51.7, 123.8, 138.5, 148.3, 164.4. Anal. Calcd 
for C13H15N9Br2: C, 34.16; H, 3.31; N, 27.58%. Found: C, 34.38; H, 3.24; N, 27.24%. 
 
2-[2-(5-Bromopentyl)-2H-tetrazol-5-yl]-6-[1-(5-bromopentyl)-1H-tetrazol-5-yl]-pyridine (3b)  
13 
 
 
White solid (1.21 g, 2.36 mmol, 33.6 %); mp 78-80 °C; Rf = 0.41 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2925, 2857, 1651 (>C=N-), 1582 (-N=N-), 1460 (C=N, pyridine), 1434, 
1261; 
1
H NMR (300 MHz, CDCl3): δH 1.71 (4H, m, CH2), 1.93 (4H, m, CH2), 2.17 (4H, m, CH2), 
3.42 (4H, m, CH2Br), 4.76 (2H, t, J = 7.1 Hz, CH2N2), 5.16 (2H, t, J = 7.8 Hz, CH2N1), 8.12 
(1H, t, J = 7.8 Hz, pyH), 8.36 (1H, d, J = 6.9 Hz, pyH), 8.49 (1H, d, J = 6.9 Hz, pyH); 
13
C NMR 
(75.4 MHz, CDCl3): δC 25.0, 26.4, 27.2, 27.9, 28.6, 28.9, 29.7, 32.9, 49.8, 53.3, 123.9, 125.2, 
138.8, 145.2, 146.9, 151.2, 164.0. Anal. Calcd for C17H23N9Br2: C, 39.78; H, 4.52; N, 24.56%. 
Found: C, 39.83; H, 4.46; N, 24.53%. 
 
2,6-Bis-[2-(5-bromopentyl)-2H-tetrazol-5-yl]-pyridine (4b)  
 
White solid (0.10 g, 0.2 mmol, 2.8 %); mp 82-84 °C; Rf = 0.32 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2926, 2856, 1649 (>C=N-), 1581 (-N=N-), 1462 (C=N, pyridine), 1435, 
1258; 
1
H NMR (300 MHz, CDCl3): δH 1.68 (4H, m, CH2), 1.91 (4H, m, CH2), 2.19 (4H, m, CH2), 
3.41 (4H, t, J = 6.6 Hz, CH2Br), 4.77 (4H, t, J = 7.1 Hz, CH2N), 8.06 (1H, t, J = 7.8 Hz, pyH), 
8.45 (2H, d, J = 7.8 Hz, pyH); 
13
C NMR (75.4 MHz, CDCl3): δC 28.0, 28.2, 28.5, 31.8, 53.2, 
123.6, 138.4, 147.5, 164.3. Anal. Calcd for C17H23N9Br2: C, 39.78; H, 4.52; N, 24.56%. Found: 
C, 39.79; H, 4.54; N, 24.51%. 
 
2-[2-(7-Bromoheptyl)-2H-tetrazol-5-yl]-6-[1-(7-bromoheptyl)-1H-tetrazol-5-yl]-pyridine (3c)  
 
White solid (1.32 g, 2.32 mmol, 33 %); mp 64-66 °C; Rf = 0.53 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2923, 2857, 1653 (>C=N-), 1581 (-N=N-), 1464 (C=N, pyridine), 1434, 
1261; 
1
H NMR (300 MHz, CDCl3): δH 1.41 (12H, m, CH2), 1.83 (4H, m, CH2), 2.09 (4H, m, 
CH2), 3.40 (4H, m, CH2Br), 4.73 (2H, t, J = 7.1 Hz, CH2N2), 5.14 (2H, t, J = 7.4 Hz, CH2N1), 
8.10 (1H, t, J = 7.8 Hz, pyH), 8.36 (1H, d, J = 6.8 Hz, pyH), 8.48 (1H, d, J = 6.8 Hz, pyH); 
13
C 
NMR (75.4 MHz, CDCl3): δC 26.1, 26.2, 27.8, 27.9, 28.1, 28.2, 29.3, 30.0, 32.5, 32.6, 33.8, 33.9, 
50.1, 53.5, 123.8, 125.1, 138.8, 145.2, 146.9, 151.2, 164.0. Anal. Calcd for C21H31N9Br2: C, 
44.30; H, 5.49; N, 22.14%. Found: C, 44.36; H, 5.54; N, 22.17%. 
 
2,6-Bis-[2-(7-bromoheptyl)-2H-tetrazol-5-yl]-pyridine (4c) 
 
White solid (0.20 g, 0.35 mmol, 5 %); mp 70-72 °C; Rf = 0.43 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2928, 2856, 1653 (>C=N-), 1581 (-N=N-), 1463 (C=N, pyridine), 1430, 
14 
 
1260; 
1
H NMR (300 MHz, CDCl3): δH 1.37 (12H, m, CH2), 1.89 (4H, m, CH2), 2.11 (4H, m, 
CH2), 3.44 (4H, t, J = 7.3 Hz, CH2Br), 4.76 (4H, t, J = 7.3 Hz, CH2N), 8.12 (1H, t, J = 7.7 Hz, 
pyH), 8.36 (2H, d, J = 7.8 Hz, pyH); 
13
C NMR (75.4 MHz, CDCl3): δC 27.2, 28.6, 28.7, 29.8, 
32.7, 34.1, 53.6, 123.5, 138.3, 147.6, 164.2. Anal. Calcd for C21H31N9Br2: C, 44.30; H, 5.49; N, 
22.14%. Found: C, 44.26; H, 5.44; N, 22.09%. 
 
2-[2-(9-Bromononyl)-2H-tetrazol-5-yl]-6-[1-(9-bromononyl)-1H-tetrazol-5-yl]-pyridine (3d)  
 
White solid (1.61 g, 2.6 mmol, 36.7 %); mp 51-53 °C; Rf = 0.67 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2923, 2857, 1653 (>C=N-), 1581 (-N=N-), 1464 (C=N, pyridine), 1434, 
1261; 
1
H NMR (300 MHz, CDCl3): δH 1.34 (12H, m, CH2), 1.61 (8H, m, CH2), 1.83 (4H, m, 
CH2), 2.08 (4H, m, CH2), 3.40 (4H, m, CH2Br), 4.72 (2H, t, J = 7.1 Hz, CH2N2), 5.16 (2H, t, J = 
7.3 Hz, CH2N1), 8.09 (1H, t, J = 8.1 Hz, pyH), 8.36 (1H, d, J = 7.8 Hz, pyH), 8.48 (1H, d, J = 7.8 
Hz, pyH); 
13
C NMR (75.4 MHz, CDCl3): δC 24.7, 24.8, 24.9, 25.0, 25.1, 25.1, 25.2, 25.3, 25.3, 
25.4, 25.5, 26.4, 27.2, 28.9, 28.1, 29.7, 32.9, 49.7, 53.3, 123.9, 125.2, 138.7, 145.4, 146.8, 151.3, 
164.4. Anal. Calcd for C25H39N9Br2: C, 48.01; H, 6.29; N, 20.16%. Found: C, 48.06; H, 6.28; N, 
20.19%. 
 
2,6-Bis-[2-(9-bromononyl)-2H-tetrazol-5-yl]-pyridine (4d) 
 
White solid (0.20 g, 0.3 mmol, 4.6 %); mp 58-60 °C; Rf = 0.54 (60:40 petroleum ether/ethyl 
acetate); IR (KBr, cm
-1
): 2925, 2855, 1651 (>C=N-), 1582 (-N=N-), 1460 (C=N, pyridine), 1434, 
1261; 
1
H NMR (300 MHz, CDCl3): δH 1.37 (16H, m, CH2), 1.61 (4H, m, CH2), 1.89 (4H, m, 
CH2), 2.11 (4H, m, CH2), 3.40 (4H, t, J = 7.1 Hz, CH2Br), 4.72 (4H, t, J = 7.1 Hz, CH2N), 8.12 
(1H, t, J = 7.7 Hz, pyH), 8.36 (2H, d, J = 7.8 Hz, pyH); 
13
C NMR (75.4 MHz, CDCl3): δC 26.3, 
26.8, 27.2, 28.6, 28.7, 29.8, 32.7, 34.0, 53.5, 123.5, 138.3, 147.6, 164.2. Anal. Calcd for 
C25H39N9Br2: C, 48.01; H, 6.29; N, 20.16%. Found: C, 48.10; H, 6.32; N, 20.21%. 
 
General Syntheses of di-pyridyl-tetra-tetrazole macrocycles (5a-d) 
 
A mixture of 2 (0.86 g, 4.0 mmol) and potassium carbonate (2.78 g, 20.0 mmol) in anhydrous 
dimethylformamide (50 ml) was stirred at 75 °C under a nitrogen atmosphere, then treated with 
3a-d (4.0 mmol) and stirred at 75 °C for 24 hours. The insoluble salts, which were removed from 
the cooled mixture by filtration, were washed with ethyl acetate. The combined washings and 
mother-liquor were evaporated under reduced pressure. The residue was dissolved in chloroform 
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and chromatographed on a silica gel column using ethyl acetate:petroleum ether (70:30 v/v) as 
eluent to give a white solid. Only 
1
H NMR data was obtained for all mixtures. 
 
Macrocycle 5a  
1
H NMR (300 MHz, CDCl3): δH 1.97 (4H, br m, CH2), 4.75 (4H, br t, CH2N2), 5.27 (4H,br t, 
CH2N1), 8.15 (2H, br t, pyH), 8.35 (2H, br d, pyH), 8.48 (2H, br d, pyH). 
 
Macrocycle 5b  
1
H NMR (300 MHz, CDCl3): δH 1.42 (8H, br m, CH2), 1.83 (4H, br m, CH2), 4.79 (4H, br t, 
CH2N2), 5.23 (4H,br t, CH2N1), 8.14 (2H, br t, pyH), 8.33 (2H, br d, pyH), 8.50 (2H, br d, pyH). 
 
Macrocycle 5c  
1
H NMR (300 MHz, CDCl3): δH 1.45 (12H, br m, CH2), 1.79 (8H, br m, CH2), 4.72 (4H, br t, 
CH2N2), 5.30 (4H, br t, CH2N1), 8.18 (2H, br t, pyH), 8.39 (2H, br d, pyH), 8.46 (2H, br d, pyH). 
 
Macrocycle 5d  
1
H NMR (300 MHz, CDCl3): δH 1.35 (12H, br m, CH2), 1.65 (8H, br m, CH2), 1.81 (8H, br m, 
CH2), 4.73 (4H, br t, CH2N2), 5.12 (4H, br t, CH2N1), 8.09 (2H, br t, pyH), 8.04 (1H, d, J = 6.8 
Hz, pyH), 8.17 (2H, m, ArH), 8.31 (1H, d, J = 6.7 Hz, pyH), 8.41 (1H, s, ArH). 
 
General Syntheses of pyridyl-tetra-tetrazole macrocycles (7a-d) 
 
A mixture of 6 (0.86 g, 4.0 mmol) and potassium carbonate (2.78 g, 20.0 mmol) in anhydrous 
dimethylformamide (50 ml) was stirred at 75 °C under a nitrogen atmosphere, then treated with 
3a-d (4.0 mmol) and stirred at 75 °C for 24 hours. The insoluble salts, which were removed from 
the cooled mixture by filtration, were washed with ethyl acetate. The residue was dissolved in 
chloroform and chromatographed on a silica gel column using ethyl acetate:petroleum ether 
(70:30 v/v) as eluent to give the pyridine tetra-tetrazolophane macrocycles (7a-d).  
 
Macrocycle 7a  
White crystalline solid (0.43 g, 0.84 mmol, 21 %); mp 210-212 °C; Rf = 0.03 (50:50 petroleum 
ether/ethyl acetate); IR (KBr, cm
-1
): 2926, 2851, 1654 (>C=N-), 1596 (-N=N-), 1458 (C=N, 
pyridine), 1433, 1261; 
1
H NMR (300 MHz, CDCl3): δH 1.67 (4H, m, CH2), 4.74 (2H, m, CH2N2), 
5.03 (4H, m, CH2N2), 5.30 (2H, t, J = 7.1 Hz, CH2N1), 7.60 (1H, t, J = 7.6 Hz, ArH), 7.91 (1H, t, 
J = 7.9 Hz, pyH), 8.04 (1H, d, J = 6.8 Hz, pyH), 8.17 (2H, m, ArH), 8.31 (1H, d, J = 6.7 Hz, 
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pyH), 8.41 (1H, s, ArH); 
13
C NMR (75.4 MHz, CDCl3): δC 29.4, 29.7, 46.1, 49.4, 50.4, 51.3, 
123.9, 125.7, 125.8, 127.8, 128.1, 128.2, 128.8, 129.8, 138.7, 144.5, 146.8, 151.5, 163.9, 164.2, 
164.6; HRMS (M+H)
+
 calcd for C21H20N17 = 510.2009, found = 510.2085. Anal. Calcd for 
C21H19N17: C, 49.51; H, 3.76; N, 46.74%. Found: C, 49.62; H, 3.88; N, 46.91%. 
 
Macrocycle 7b  
White crystalline solid (0.45 g, 0.79 mmol, 20 %); mp 195-197 °C; Rf = 0.16 (50:50 petroleum 
ether/ethyl acetate); IR (KBr, cm
-1
): 2925, 2855, 1654 (>C=N-), 1596 (-N=N-), 1458 (C=N, 
pyridine), 1433, 1261; 
1
H NMR (300 MHz, CDCl3): δH 1.64 (4H, m, CH2), 2.19 (8H, m, CH2), 
4.74 (6H, m, CH2N2), 5.10 (2H, t, J = 7.2 Hz, CH2N1), 7.68 (1H, t, J = 7.8 Hz, ArH), 7.94 (1H, t, 
J = 7.9 Hz, pyH), 8.13 (1H, d, J = 6.8 Hz, pyH), 8.31 (2H, m, ArH), 8.40 (1H, d, J = 6.8 Hz, 
pyH), 8.69 (1H, s, ArH); 
13
C NMR (75.4 MHz, CDCl3): δC 23.4, 23.5, 28.1, 28.3, 28.8, 29.4, 
49.7, 52.3, 53.0, 53.1, 123.8, 125.2, 125.5, 128.0, 128.2, 128.3, 128.4, 129.7, 138.6, 145.0, 146.7, 
151.4, 164.0, 164.2, 164.6; HRMS (M+H)
+
 calcd for C25H28N17 = 566.2635, found = 566.2695. 
Anal. Calcd for C25H27N17: C, 53.09; H, 4.81; N, 42.10%. Found: C, 52.89; H, 4.71; N, 42.54%. 
 
Macrocycle 7c  
White crystalline solid (0.43 g, 0.69 mmol, 17.3 %); mp 185-187 °C; Rf = 0.35 (50:50 petroleum 
ether/ethyl acetate); IR (KBr, cm
-1
): 2924, 2855, 1658 (>C=N-), 1597 (-N=N-), 1459 (C=N, 
pyridine), 1432, 1261; 
1
H NMR (300 MHz, CDCl3): δH 1.43 (10H, m, CH2), 2.08 (10H, m, CH2), 
4.70 (6H, m, CH2N2), 5.10 (2H, t, J = 7.2 Hz, CH2N1), 7.64 (1H, t, J = 7.7 Hz, ArH), 8.04 (1H, t, 
J = 7.9 Hz, pyH), 8.25 (1H, d, J = 7.0 Hz, pyH), 8.32 (2H, m, ArH), 8.44 (1H, d, J = 6.9 Hz, 
pyH), 8.83 (1H, s, ArH); 
13
C NMR (75.4 MHz, CDCl3): δC 25.6, 25.8, 26.1, 26.2, 27.6, 28.4, 
28.8, 29.2, 29.7, 29.9, 49.9, 52.8, 53.2, 53.4, 123.8, 125.2, 125.3, 128.2, 128.3, 128.4, 128.5, 
129.7, 138.7, 145.2, 146.9, 151.3, 163.9, 164.4, 164.6; HRMS (M+H)
+
 calcd for C29H36N17 = 
622.3261, found = 622.3317. Anal. Calcd for C29H35N17: C, 56.03; H, 5.67; N, 38.30%. Found: 
C, 56.34; H, 5.83; N, 38.19%. 
 
Macrocycle 7d  
White crystalline solid (0.41 g, 0.61 mmol, 15 %); mp 167-168 °C; Rf = 0.58 (50:50 petroleum 
ether/ethyl acetate); IR (KBr, cm
-1
): 2920, 2852, 1656 (>C=N-), 1596 (-N=N-), 1459 (C=N, 
pyridine), 1434, 1260; 
1
H NMR (300 MHz, CDCl3): δH 1.33 (22H, m, CH2), 2.07 (10H, m, CH2), 
4.69 (6H, m, CH2N2), 5.12 (2H, t, J = 7.3 Hz, CH2N1), 7.64 (1H, t, J = 7.2 Hz, ArH), 8.07 (1H, t, 
J = 7.8 Hz, pyH), 8.29 (3H, m, pyH & ArH), 8.46 (1H, d, J = 6.9 Hz, pyH), 8.89 (1H, s, ArH); 
13
C NMR (75.4 MHz, CDCl3): δC 25.8, 26.1, 28.3, 28.4, 28.7, 28.8, 28.9, 29.0, 29.1, 29.2, 29.3, 
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29.7, 30.3, 50.1, 53.1, 53.3, 53.5, 123.7, 125.1, 125.2, 128.3, 128.4, 129.6, 138.7, 145.2, 146.9, 
151.3, 163.9, 164.4, 164.5; HRMS (M+H)
+
 calcd for C33H44N17 = 678.3887, found = 678.3944. 
Anal. Calcd for C33H43N17: C, 58.48; H, 6.39; N, 35.13%. Found: C, 58.34; H, 6.43; N, 35.19%. 
 
Crystallography 
 
Data for 3b and 7c were collected at 150(2)K on a Bruker Apex II CCD diffractometer using 
MoKα radiation (λ = 0.71073Å). The structures were solved by direct methods and refined on F
2
 
using all the reflections.
20
 All the non-hydrogen atoms were refined using anisotropic atomic 
displacement parameters and hydrogen atoms were inserted at calculated positions using a riding 
model. Crystallographic data for 3b and 7c has been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication number 799907 and 799908. Copies 
of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge 
CB2 1EZ, UK (Fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk). 
 
Compound 3b. Crystal data: C17H23Br2N9, M = 513.26, orthorhombic, a = 9.99029(19), b = 
10.2310(19), c = 40.898(8) Å, U = 4143.6(13) Å
3
, space group Pbca, Z = 8, μ = 3.936 mm-1, calc 
= 1.646 Mg.cm
–3
. 28973 data (3639 unique, Rint = 0.1246) were measured in the range 1.99 < θ < 
25.00˚. R1(I > 2σ(I)) = 0.0883 and wR2(all data) = 0.2113. Goodness of fit on F
2
 = 1.178. CCDC 
No. 799907. 
 
Compound 7c. Crystal data: C29H35N17, M = 621.74, monoclinic, a = 11.5821(13), b = 
8.1191(9), c = 32.691(4) Å, β = 90.034(2)º, U = 3074.1(6) Å3, space group P21/c, Z = 4, μ = 
0.090 mm
-1
, calc = 1.343 Mg.cm
–3
. 26150 data (6321 unique, Rint = 0.0478) were measured in the 
range 1.76 < θ < 26.42˚. R1(I > 2σ(I)) = 0.0432 and wR2(all data) = 0.1087. Goodness of fit on F
2
 
= 1.021. CCDC No. 799908. 
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Synthesis and characterisation of macrocycles containing both tetrazole and 
pyridine functionalities 
 
Adrienne Fleming, Jackie Gaire, Fintan Kelleher, John McGinley, and Vickie McKee. 
 
 
The syntheses of tetra-tetrazole 
macrocycles containing at least one 
2,6-bis(tetrazole)pyridine unit, linked 
by a variety of n-alkyl (n = 3, 5, 7 or 9 
carbon atoms) chain lengths, are 
described. There has been no previous 
incorporation of the pyridine moiety 
into a tetra-tetrazolophane macrocycle. 
 
 
 
